Literature DB >> 17047386

Cancers associated with acromegaly.

Paul J Jenkins1.   

Abstract

Acromegaly is characterised by excessive levels of circulating growth hormone and its tissue mediator, insulin-like growth factor (IGF)-I. Prior to effective treatment and lowering of growth hormone and IGF-I, the majority of patients with the disease died by the age of 60 years, largely due to diabetes mellitus, cardiovascular and cerebrovascular diseases. More recently, it has become apparent that patients with acromegaly may also have an increased prevalence of colorectal adenomas and cancer. This may be due to elevated IGF-I, which is implicated in the development of sporadic colorectal cancer, and environmental factors, such as the bile acid deoxycholic acid, the levels of which are also increased in acromegaly. There is some evidence to suggest that breast and prostatic malignancies might also be increased in acromegaly. However, these associations have been based mostly on small epidemiological surveys and circumstantial evidence. Large-scale epidemiological studies are required to clarify this issue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047386     DOI: 10.1159/000095531

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  20 in total

Review 1.  [Hormone therapy and anti-aging: is there an indication?].

Authors:  D Heutling; H Lehnert
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

2.  Thyroid cancer is the most common cancer associated with acromegaly.

Authors:  Bennur Esen Gullu; Ozlem Celik; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

3.  Increased thyroid cancer risk in acromegaly.

Authors:  Selcuk Dagdelen; Nese Cinar; Tomris Erbas
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

4.  Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up.

Authors:  F Guaraldi; D Gori; G Beccuti; N Prencipe; R Giordano; Y Mints; V S Di Giacomo; A Berton; M Lorente; V Gasco; E Ghigo; R Salvatori; S Grottoli
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

5.  Human growth hormone abuse in male weightlifters.

Authors:  Brian P Brennan; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Am J Addict       Date:  2010-11-12

Review 6.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

7.  Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly.

Authors:  C L Ronchi; F Coletti; E Fesce; L Montefusco; C Ogliari; E Verrua; P Epaminonda; E Ferrante; E Malchiodi; V Morelli; P Beck-Peccoz; M Arosio
Journal:  J Endocrinol Invest       Date:  2009-04-29       Impact factor: 4.256

8.  Recreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk.

Authors:  Sana Khoury-Shakour; Stephen B Gruber; Flavio Lejbkowicz; Hedy S Rennert; Leon Raskin; Mila Pinchev; Gad Rennert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

9.  Efficacy and complications of neurosurgical treatment of acromegaly.

Authors:  Anna Krzentowska-Korek; Filip Gołkowski; Agata Bałdys-Waligórska; Alicja Hubalewska-Dydejczyk
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

Review 10.  Growth hormone measurements in the diagnosis and monitoring of acromegaly.

Authors:  Akira Sata; Ken K Y Ho
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.